Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

October 7, 2018 | APPEARED IN VOLUME 96, ISSUE 40


Ineos plans to expand its phenol plant in Mobile, Ala., by more than 50%. The firm says the plant’s new capacity of 850,000 metric tons per year will make it the largest producer of phenol in the world.

Cabot has acquired a 50,000-metric-ton-per-year carbon black plant in Pizhou, China, from Nippon Steel Chemical & Material. Cabot will initially halt production at the site for maintenance work to raise environmental performance.

Venator will continue talks with Tronox to buy a Cristal-owned titanium dioxide plant in Ashtabula, Ohio, despite expiration of their exclusive negotiating period. The sale would help the merger of Cristal and Tronox clear regulatory review.

Wyatt Technology, a California-based scientific instrument maker, has acquired Superon, a German maker of field flow fractionation instruments that spun off from Wyatt in 2012. Superon’s technology complements Wyatt’s expertise in macromolecular and nanoparticle characterization.

Pivot Bio has raised $70 million in a series B financing round. The firm says it will use the funds to expand R&D and advance its nitrogen-producing microbes as an alternative to nitrogen-containing fertilizers.

Roche will pay GO Therapeutics $9 million in upfront and near-term milestones as part of a deal to develop glycotargeting bispecific antibodies. GO’s technology takes advantage of the aberrant O-linked glycans found on tumor cells, but not normal cells, to develop safer, targeted immunotherapies.

Merck & Co. will work with Dragonfly Therapeutics to discover and develop immunotherapies for patients with solid tumors. The pact, based on Dragonfly’s TriNKET technology, could be worth up to $695 million for Dragonfly.

Boston Pharmaceuticals has acquired three anti-infective programs from Novartis, which is exiting antibiotics R&D. Boston has also acquired five new drug programs no longer wanted by GlaxoSmithKline.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment